17
Complete Baseline Evaluation
• SCD risk assessment
• Stress testing if symptomatic, if LVOTO is suspected but
unconfirmed, or to determine baseline functional capacity
Every 1–2 years or with any change in symptoms*
Serial evaluation for clinical status, SCD risk, AF risk,
or any change in symptoms:
• Clinical assessment
• Echo
• Ambulatory ECG monitor
(1)
2
Phenotype Positive
Asymptomatic Adults
Children and/or Symptomatic Adults
Every 2–3 y
Treadmill exercise or
Cardiopulmonary exercise testing
for assessment of functional
status
(2b)
Exercise testing
Special consideration:
• Stress echo if gradient <50 mm Hg
• CPET if considering advanced HF
therapies
(1)
Every 3–5 y
CMR for SCD risk assessment (if no ICD present), or
to evaluate for any suspected morphologic changes
(2b)
CMR indicates cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test;
ECG, electrocardiography/electrocardiogram; HCM, hypertrophic cardiomyopathy; HF,
heart failure; ICD, implantable cardioverter-defibrillator; LVOTO, le ventricular outflow
tract obstruction; P/LP, pathogenic or likely pathogenic variant; SCD, sudden cardiac death;
and VUS, variant of unknown significance.